Cover Image

Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation

Recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) is a rare but challenging condition. In most cases, the recurrent tumor is presented with extrahepatic spread. Therefore, systemic treatment with sorafenib has to be assessed. Because of a plethora of possible drug interaction...

Full description

Saved in:
Bibliographic Details
Main Authors: Pfeiffenberger, Jan (Author) , Koschny, Ronald (Author) , Hoffmann, Katrin (Author) , Mehrabi, Arianeb (Author) , Schmitz, Anne (Author) , Radeleff, Boris (Author) , Stremmel, Wolfgang (Author) , Schemmer, Peter (Author) , Ganten, Tom M. (Author)
Format: Article (Journal)
Language:English
Published: 4 October 2013
In: Langenbeck's archives of surgery
Year: 2013, Volume: 398, Issue: 8, Pages: 1123-1128
ISSN:1435-2451
DOI:10.1007/s00423-013-1114-1
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00423-013-1114-1
Get full text
Author Notes:Jan Pfeiffenberger, Ronald Koschny, Katrin Hoffmann, Arianeb Mehrabi, Anne Schmitz, Boris Radeleff, Wolfgang Stremmel, Peter Schemmer, Tom M. Ganten
Description
Summary:Recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) is a rare but challenging condition. In most cases, the recurrent tumor is presented with extrahepatic spread. Therefore, systemic treatment with sorafenib has to be assessed. Because of a plethora of possible drug interactions, e.g., with immunosuppressant or anti-infective therapy, safety and feasibility of sorafenib treatment requires special attention.
Item Description:Gesehen am 20.01.2022
Physical Description:Online Resource
ISSN:1435-2451
DOI:10.1007/s00423-013-1114-1

Similar Items